SCHEMBL5004384

SCHEMBL5004384

CC1(C)CCN(c2ccc(OC(=O)N3CCc4cc(Cl)ccc4C3)nc2)C(=O)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.38
TACR3 P29371 1/20 0.37
ACHE P22303 1/20 0.37
ESR2 Q92731 1/20 0.36
HRH3 Q9Y5N1 5/20 0.36
LIPE Q05469 2/20 0.35
HRH1 P35367 1/20 0.35
HPGD P15428 2/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
CHRM4 P08173 2/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
AKR1C3 P42330 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998738 0.97 GRM5 (0.38) GRM5TACR3ACHEHRH3LIPE
SCHEMBL4989312 0.90 GRM5 (0.40) GRM5ACHEESR2HRH3LIPE
SCHEMBL4998517 0.89 ABHD6 (0.44) ACHEESR2HRH3LIPEHRH1
SCHEMBL4998728 0.89 PKM (0.41) TACR3ACHEESR2LIPEHPGD
SCHEMBL5002110 0.88 LIPE (0.46) GRM5ACHELIPEHPGDMAPT
SCHEMBL4996224 0.87 GRM5 (0.40) GRM5ACHEHRH3LIPEHRH1
SCHEMBL4989335 0.87 KMT2A (0.42) HPGDMAPTHTTNPSR1
SCHEMBL4998259 0.85 HRH3 (0.41) ACHEESR2HRH3LIPEHRH1
SCHEMBL4998689 0.85 PKM (0.41) TACR3ACHEESR2LIPEHPGD
SCHEMBL5004383 0.83 ESR2 (0.36) TACR3ACHEESR2LIPEHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227792-A1 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters NOVO NORDISK A/S (DK) 2008-09-18 US claimed
US-20080227792-A1 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters NOVO NORDISK A/S (DK) 2008-09-18 US disclosed
EP-1853585-A1 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS Novo Nordisk A/S (DK) 2007-11-14 EP disclosed
WO-2006087309-A1 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS NOVO NORDISK A/S (DK) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227792-A1 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters LIPE, LIPC, PNLIP GRM5 2390/4885TACR3 3452/4885ACHE 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.